Lightstone Singapore
SelectiveBoston, MAHealthcare, Biotechnology, PharmaceuticalsLast fund filed 2016
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Lightstone Singapore | 2016 | $50M | $50M | 2 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Henry Plain, Jr. | Slowing | Medical devices, Biotech & pharma, Climate & energy | 9 |
Classified sectors of Lightstone Singapore’s own portfolio companies, based on 25 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Lightstone Ventures | 26 | ACCELERON PHARMA, Apreo Health, Cala Health, Calithera Biosciences, CATABASIS PHARMACEUTICALS, CLARET MEDICAL, Cyteir Therapeutics, EarLens, ENDOGASTRIC SOLUTIONS, ExploraMed NC7, Gemini Therapeutics, GLUMETRICS, GYNESONICS, HOLAIRA, HYDRA BIOSCIENCES, Imperative Care, Kona Medical, MediSix Therapeutics, MIRAMAR LABS, MIRAMAR LABS, Moximed, PowerVision, SHOULDER INNOVATIONS, Tallac Therapeutics, Thrasos Innovation, TWELVE |
| Domain Partners | 3 | Kona Medical, MIRAMAR LABS, TWELVE |
| NEA | 3 |
| 1 |
| Michael Carusi | Slowing | Medical devices, Biotech & pharma, Digital health | 12 | 1 |
| Jean George | Quiet | Biotech & pharma, Healthcare services | 7 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Lightstone Singapore’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| ExploraMed NC7, Foundry Therapeutics 1, Moximed |
| Versant Venture Capital | 3 | GLUMETRICS, HOLAIRA, TWELVE |
| Abingworth Bioventures | 2 | GYNESONICS, HYDRA BIOSCIENCES |
| Aisling Capital | 2 | EarLens, PowerVision |
| Bain Capital Life Sciences | 2 | GYNESONICS, Imperative Care |
| Caduceus Capital | 2 | ACCELERON PHARMA, Gemini Therapeutics |
| Orbimed Asia Partners | 2 | ACCELERON PHARMA, Gemini Therapeutics |
| Orbimed Genesis | 2 | ACCELERON PHARMA, Gemini Therapeutics |
| Advent Life Sciences | 1 | Moximed |
| Atlas Venture | 1 | Gemini Therapeutics |
| Baird Venture Partners | 1 | Cala Health |
| Clarus | 1 | CATABASIS PHARMACEUTICALS |
| IPI Partners | 1 | SHOULDER INNOVATIONS |
A shared board seat: a company where filings name a Lightstone Singapore partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.